|
Published by: Mintel International Group Ltd.
Published: Mar. 1, 2003 - 106 Pages
Table of Contents
Introduction & Abbreviations
Introduction
Other Relevant Reports
Definition
Abbreviations & Terms
Abbreviations
Terms
Executive Summary
An Aging Population
No Relief From Pain
Transition From Rx To Otc
Increase In Condition-Specific Products
New Formulations Offer Hope
Two Major Segments
Four Manufacturers Control The Market
Supermarkets And Drug Stores Are Yielding To Mass Merchandisers
The Consumer
The Future Of Analgesics
Market Drivers
An Aging Population
Figure 1 U.S. Population Projections, By Age, 2000-2010
Shrinking Child Population
Americans Are Dealing With Chronic Pain
Handling Headaches
Incidence And Extent Of Arthritis
Growing Concerns Over Cox-2
Self-Medication Provides A Solution
Figure 2 Incidence Of Specific Ailments And Level Of Otc Treatment, 2001
Aspirin's Cardio-Protective Effects
Competition In The Market
External Analgesics
Growth Of Private Brands
Growing Alternatives For Pain Relief
Rx Comes Over The Counter
Market Size & Trends
Market Size
Figure 3 Retail Sales Of Otc Internal Analgesics, At Current And Constant Prices, 1997-2002
Graph 1 Trends In Sales Of Analgesics, At Current And Constant Prices, 1997-2002
Trends
Condition-Specific Products Go Right To The Source
New Formulations Offer Hope Of Reviving Market
Fda Requires Usage Warnings
Market Segmentation
Overview
Figure 4 Retail Sales Of Otc Internal Analgesics, By Type, 2000 & 2002
Graph 2 Trends In Fdm Sales Of Analgesics, By Segment, 1997-2002
Tablets
Figure 5 Retail Sales Of Otc Internal Tablet Analgesics, At Current And Constant Prices, 1997-2002
Liquids
Figure 6 Retail Sales Of Otc Internal Liquid Analgesics, At Current And Constant Prices, 1997-2002
Supply Structure
Manufacturer Sales
Figure 7 Fdm Manufacturer Sales Of Internal Analgesics, 2000 & 2002
Graph 3 Manufacturer Share Of Fdm Analgesics Sales, 2002
Brand Sales By Segment
Tablet Analgesics
Figure 8 Fdm Brand Sales Of Analgesic Tablets, 2000 & 2002
Liquid Analgesics
Figure 9 Fdm Brand Sales Of Analgesic Liquids, 2000 & 2002
Companies And Brands
Mcneil Ppc
Wyeth Consumer Healthcare
Bayer Consumer Care
Bristol-Myers Squibb
Perrigo Company And Private Label
Advertising & Promotion
Overview
Company Activity
Bayer
Bristol-Myers Squibb
Mcneil Ppc
Wyeth Consumer Healthcare
Retail Distribution
Overview
Figure 10 Retail Sales Of Otc Internal Analgesics, By Channel, 2000 & 2002
Graph 4 Trends In Sales Of Analgesics, By Channel, 1997-2002
Supermarkets
Figure 11 Supermarket Sales Of Otc Internal Analgesics, 1997-2002
Supermarket Retailers
Figure 12 Top Supermarkets By Sales, 2001 And 2002
Drug Stores
Figure 13 Drug Store Sales Of Otc Internal Analgesics, 1997-2002
Drug Store Retailers
Figure 14 Top Drug Store Retailers, By Number Of Stores, April 2002
Figure 15 Top Drug Store Retailers By Sales, Financial Years Ending 2001 & 2002
Mass Merchandisers
Figure 16 Mass Merchandiser Sales Of Otc Internal Analgesics, 1997-2002
Mass Merchandiser Retailers
Figure 17 Number Of Mass Merchandiser Retailers, September 2002
Figure 18 Top Mass Merchandiser Retailers, By Sales, 2001 & 2002
The Consumer
Introduction
Usage Of Internal Analgesics
Figure 19 Use Of Headache/Pain Relievers, April 2001-May 2002
Figure 20 Use Of Otc Pain Relievers, By Gender, April 2001-May 2002
Figure 21 Use Of Otc Pain, By Age, April 2001-May 2002
Figure 22 Use Of Otc Pain Relievers, By Race/Ethnicity, April 2001-May 2002
Form Of Pain Relief Taken
Figure 23 Form Of Headache/Pain Relievers Taken, April 2001-May 2002
Figure 24 Form Of Headache/Pain Relievers Taken, By Gender, April 2001-May 2002
Figure 25 Form Of Headache/Pain Relievers Taken, By Age, April 2001-May 2002
Type Of Pain Relief Taken
Figure 26 Types Of Headache/Pain Relievers Taken, April 2001-May 2002
Figure 27 Types Of Headache/Pain Relievers Taken, By Gender, April 2001-May 2002
Figure 28 Types Of Headache/Pain Relievers Taken, By Age, April 2001-May 2002
Figure 29 Types Of Headache/Pain Relievers Taken, By Race/Ethnicity, April 2001-May 2002
Reasons For Taking Pain Relief By Type Taken
Figure 30 Type By Reason, April 2001-May 2002 (Part 1)
Figure 31 Type By Reason, April 2001-May 2002 (Part 2)
Strength Of Analgesic Used
Figure 32 Strength Of Headache/Pain Reliever Taken, April 2001-May 2002
Figure 33 Strength Of Headache/Pain Reliever Taken, By Gender, April 2001-May 2002
Figure 34 Strength Of Headache/Pain Relievers Taken, By Age, April 2001-May 2002
Figure 35 Strength Of Headache/Pain Relievers Taken, By Race/Ethnicity, April 2001-May 2002
Brand Loyalty
Figure 36 Brands Of Headache/Pain Reliever Used, April 2001-May 2002
Figure 37 Brand Preference Of Headache/Pain Relievers, By Age, April 2001-May 2002
Figure 38 Brand Preference Of Headache/Pain Relievers, By Race/Ethnicity, April 2001-May 2002
Frequency Of Usage
Figure 39 Frequency Of Use Of Otc Pain Relievers, April 2001-May 2002
Figure 40 Frequency Of Use Of Otc Pain Relievers In Past 30 Days, By Age, April 2001-May 2002
Figure 41 Frequency Of Taking Headache/Pain Relievers, By Purpose Used For, April 2001-May 2002 (Part 1)
Figure 42 Frequency Of Taking Headache/Pain Relievers, By Purpose Used For, April 2001-May 2002 (Part 2)
Reasons For Taking Pain Relief
Figure 43 Reasons For Taking Pain Relief, April 2001-May 2002
Figure 44 Reasons For Taking Pain Relief, By Gender, April 2001-May 2002
Figure 45 Reasons For Taking Pain Relief, By Age Of Head Of Household, April 2001-May 2002
Figure 46 Reasons For Taking Pain Relief, By Race/Ethnicity, April 2001-May 2002
Where Pain Relievers Are Bought
Figure 47 Where Pain Relievers Are Bought, January 2003
Figure 48 Where Pain Relievers Are Bought, By Gender, January 2003
Figure 49 Where Pain Relievers Are Bought, By Age, January 2003
Figure 50 Where Pain Relievers Are Bought, By Household Income, January 2003
Figure 51 Where Pain Relievers Are Bought, By Region, January 2003
Figure 52 Where Pain Relievers Are Bought, By Race, January 2003
Attitudes Towards Buying Otc Pain Relievers
Figure 53 Attitudes Towards Buying Otc Pain Relievers, January 2003
Figure 54 Attitudes Towards Buying Otc Pain Relievers, By Gender, January 2003
Figure 55 Attitudes Towards Buying Otc Pain Relievers, By Age, January 2003
Figure 56 Attitudes Towards Buying Otc Pain Relievers, By Income, January 2003
Figure 57 Attitudes Towards Buying Otc Pain Relievers, By Region, January 2003
Figure 58 Attitudes Towards Buying Otc Pain Relievers, By Race, January 2003
Teenage Use Of Pain Relief
Figure 59 Teenage Use Of Headache/Pain Relievers Taken, By Gender, April 2001-May 2002
Figure 60 Teenage Use Of Headache/Pain Relievers Taken, By Age, April 2001-May 2002
Use Of Otc Fever/Pain Relievers By Children
Figure 61 Children's Use Of Headache/Pain Relievers Taken, By Age Of Child In Household, April 2001-May 2002
Figure 62 Children's Use Of Headache/Pain Relievers Taken, By Frequency, April 2001-May 2002
Summary
Future & Forecast
Future Trends
An Aging Population
Pain Continues
Growing Interest In Self-Medication
Competition From External Analgesics And Natural Products
Growth Of Private Label Brands
Transition From Rx To Otc
Analgesics' Preventative Effects
Fda Usage Warnings
Third Class Of Drugs
Market Forecast
Overview
Figure 63 Forecast Of U.S. Retail Sales Of Otc Internal Analgesics, At Current And Constant Prices, 2002-2007
Graph 6 Trends In Sales Of Analgesics, At Current And Constant Prices, 2002-2007
Tablets
Figure 64 Forecast Of U.S. Retail Sales Of Otc Tablet Analgesics, At Current And Constant Prices, 2002-2007
Liquids
Figure 65 Forecast Of U.S. Retail Sales Of Otc Liquid Analgesics, At Current And Constant Prices, 2002-2007
Forecast Factors
Appendix: Trade Associations
New Product Developments
New Product Briefs
Whitehall-Robins (Wyeth): Children's Advil Ibuprofen Oral Suspension
Bristol-Myers Squibb: Excedrin Quicktabs
Target: Target Junior Strength Acetaminophen
Walgreens: Walgreens Arthritis Pain Relief
Bayer Consumer Care: Bayer Back & Body Pain Reliever Caplets
Brooks Pharmacy: Brooks Infants' Pedia Relief
Stop & Shop Supermarket: Stop & Shop Pms Formula Premenstrual Symptom Reliever
Cvs Drugstores: Cvs Added Strength Headache Relief Tablets
Target: Target Menstrual Relief Caplets
Research Methodology
Consumer Research
Sampling & Weighting
Presentation & Definition
Further Analysis
Trade Research
Informal Trade Research
Formal Trade Research
Desk & Internet Research
Sources
Definitions
Forecasts
Appendix: What Is Mintel?
Mintel Publications
Mintel Services
Product Retrieval
Retail Audits
Tailored Research
Global New Products Database
Research Support/Consultancy/Mic
The Mintel Information Centre (Mic)
Pr Research
AbstractThe U.S. analgesics market is mature, with growth over the review period principally coming from new incarnations of existing products. Although the overall internal analgesic market has been losing sales since 2000 (down 6% since 1999), its volume sales make it the strongest force in the OTC drug category. Analgesics are a staple in most households, and while consumers purchase the average personal care product 3.9 times annually, nearly 81% of households buy internal analgesics 4.2 times a year, according to ACNielsen.
Consumers have a wide range of choices in terms of type of pain reliever (aspirin, acetaminophen, ibuprofen, naproxen sodium and ketoprofen), condition specific treatments (migraine, arthritis, nighttime, premenstrual, etc.) and strength (low dose, regular, extra strength). A number of companies compete in this market and only one-McNeil PPC-holds more than 20% share.
The tablet segment, which includes caplets, capsules, gelcaps and liquid gels, accounts for over 90% of sales and despite its gradual sales decline, has seen the bulk of activity in terms of product line extensions and product repositioning over the review period, as the segment reinvents itself in response to heightened health concerns. Low-dose aspirin (81 mg) has become one of the few bright spots in the segment as more Americans turn to daily doses of aspirin to prevent heart attacks and stroke and treat arthritis.
This Mintel report explores the following hypothesis: "The OTC internal analgesic market is poised for a sales rebound given the expected growth of the older adult population, greater prevalence of arthritis, and increased use of analgesics for cardio-protective and other preventative purposes. In the face of competition from private label products and price discounts commanded by mass merchandiser giant Wal-Mart, manufacturers will turn to the increased specificity of pain relievers to convince consumers to buy a number of different products for their ailments, raising the value of their average analgesic purchase and the number of products that they keep at home."
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
